HERG Screening Market: Information By Type (Gene KCNH2, Mutant KCNH2), Ion Channel (Voltage-gated ion channel, Ligand-gated ion channel), Application (Antiarrhythmic, Antipsychotic, Antibiotics) and Region (Americas, Europe, Asia-Pacific and the Middle East and Africa) - Forecast till 2030

HERG Screening Market Overview:

HERG Screening Market is expected to register a CAGR of 12.50% during the assessment period of 2022 to 2030, to reach USD 1.63 Billion by 2030. HERG screening has been an important component of cardiac safety-pharmacology from the past many years. hERG was identified as a potassium-selective cardiac ion channel, Kv11.1, which plays an important role during cardiac repolarization.

Market Dynamics

The increasing novel drug approvals and the growing prevalence of heart diseases are driving the HERG screening market. However, the high cost of hERG screening products is expected to hamper the growth of this market during the forecast period. Nevertheless, untapped markets are likely to set a lucrative opportunity for the growth of this market in the near future.

hERG screening is primarily used for the drug discovery process. The increasing number of product launches is anticipated to boost the demand for hERG screening in the coming years. According to the annual report published by the Center for Drug Evaluation and Research (CDER), an estimated 25 drugs received novel drugs approval for marketing in 2016, whereas 59 in 2018. The increasing number of novel drugs approvals is expected to support the drugs discovery process that helps the HERG screening market to grow.

Segmentation

HERG Screening Market is segmented based on Type into ion Channel and Application.

The HERG screening  global market, on the basis of type, has been segmented into gene KCNH2 and mutant KCNH2. KCNH2 gene that provides guidelines for producing potassium channels, where this channel transports positively charged atoms of potassium out of the cells and plays a key role in generating & transmitting electrical signals. The mutation in KCNH2 causes cardiac arrhythmia. Similarly, long QT syndrome is caused by mutations in KCNH2, where an estimated 1 in 5,000–10,000 people suffered from long QT syndrome across the globe.

The HERG screening market is segmented, based on the ion channel, into voltage-gated ion channel, ligand-gated ion channel, and others. Voltage gated ion channel held the largest share of the HERG screening global market, whereas ion gated channel is the fastest-growing segment. The major factors attributed to the market growth of this segment are screening of drugs for (Human Ether-a-go-go related gene) hERG in early stages of drug discovery and development, robust growth in the pharmaceutical companies for hERG screening of lead compounds, and challenges in developing products useful for pharmaceutical and biotechnology applications.

The application segment is divided into antiarrhythmic drugs, antipsychotics, antibiotics, and others. The antiarrhythmic drug application segment is projected to hold a considerable market share. Increasing demand for drug modulation ion channel activity for its application in cardiovascular disorders, metabolic disorders, and oncology are boosting the growth of the HERG screening global market.

Regional Analysis

HERG Screening Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas market has been segmented into North America and Latin America, with North America further divided into the US and Canada. The European market for HERG screening has been segmented into Western Europe and Eastern Europe. The Western Europe HERG screening market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The market  for HERG screening in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The Middle East & Africa HERG screening market has been divided into the Middle East and Africa.

The Americas held the largest market share of 37.3% of the HERG screening market in 2019. This share can be attributed to technological development and the high prevalence of cardiac disease in the region. In 2017, according to the American College of Cardiology, emergency medical services-assessed out-of-hospital cardiac arrest occurred in an estimated 356,461 Americans. Similarly, increasing novel drug launches will support the growth of the market. According to the annual report published by the Center for Drug Evaluation and Research (CDER), an estimated 25 drugs received novel drugs approval for marketing in 2016, whereas 59 in 2018. These factors are likely to boost the growth of the market during forecast period

Key Players

The Prominent Players in the HERG Screening Market are Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS. This market are FDA approvals, joint ventures, acquisitions, expansions, and collaborations.

• In March 2020, Charles River Laboratories entered a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service. In addition to Charles River being the exclusive contract research organization distributing the Patholytix preclinical solution to clients, the organizations will work together to co-develop deep learning-enabled tools to support accelerated pathology analytics.

• In July 2017, Eurofins Scientific announced the acquisition of Discover X, a leader in drug discovery products and services across all stages of discovery from target identification and lead discovery to preclinical and beyond.

Market Segmentation

HERG Screening Market, By Type

• Gene KCNH2


• Mutant KCNH2

HERG Screening Market, By Ion Channel

• Voltage Gated


• Ligand Gated

HERG Screening Market, By Application

• Antiarrhythmic


• Antipsychotic


• Antibiotics


• Others

HERG Screening Market, By Region

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
  
  
  
  

• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • UK
    
    
    • Italy
    
    
    • Spain
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  

• Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  

• Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Available Additional Customizations

• Impact of COVID-19 on this market


• Mega Trends in the Market


• Investment Opportunities


• Pricing Analysis

Intended Audience

• Pharmaceutical companies


• Research & development organizations


• Academic institutes